-
In an open-label cross-over trial of an aromatase inhibitor in early stage post-menopausal breast cancer, patients who had become intolerant of the menopausal symptoms associated with Tamoxifen improved in this regard by switching to an aromatase inhibitor (AI).
-
The role for PET scanning is not yet established for the staging of newly-diagnosed breast cancer or for patients in whom recurrent disease is suspected.
-
-
Epidemiologic data have recently become available in the U.S. for myelodysplastic syndromes (MDS), chronic myeloproliferative disorders (CMD) and chronic myelomonocytic leukemia (CMML) after registries began including these conditions in 2001.
-
Baxter Bioscience has developed a whole-virus, two dose vaccine against avian flu; warning label now on antipsychotics regarding an increased risk of mortality in elderly patients treated for dementia-related psychosis; vitamin D for men with heart disease on horizon? A new oral anticoagulant may soon be available for prevention of thrombotic complications of hip or knee surgery; FDA Actions
-
-
The Nurses' Health Study reported an update of its data on the use of hormone therapy and stroke, focusing on the timing of initiation of treatment and the effect of estrogen doses.
-
The authors hypothesized that certain pain symptoms characterize IC/PBS. They reviewed criteria used in two recent studies to look for commonalities.
-
It has been common practice to "strip" or "sweep" membranes after 38 weeks to initiate spontaneous labor or, at least, to discourage patients from delivering after 42 weeks.
-
Berg and colleagues from 21 centers in the U.S. report the results of a prospective, multicenter, randomized trial designed to validate the performance of screening ultrasound in conjunction with mammography in women with dense breasts and at high risk for breast cancer.
